Scynexis Inc (SCYX): Ann Hanham , director of Scynexis Inc purchased 4,225 shares on May 25, 2016. The Insider buying transaction was reported by the company on May 27, 2016 to the Securities and Exchange Commission. The shares were purchased at $3.64 per share for a total value of $15,379.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 27, 2016, Marco Taglietti (CEO) purchased 5,754 shares at $3.26 per share price.On Sep 18, 2015, Gonzalez David Angulo (Chief Medical Officer) purchased 3,000 shares at $7.00 per share price.
SCYNEXIS Inc: On Wednesday, May 25, 2016 heightened volatility was witnessed in SCYNEXIS Inc which led to swings in the share price. The shares opened for trading at $3.37 and hit $3.79 on the upside , eventually ending the session at $3.3, with a gain of 1.54% or 0.05 points. The heightened volatility saw the trading volume jump to 64,618 shares. The 52-week high of the share price is $9.9 and the company has a market cap of $46 M . The 52-week low of the share price is at $2.82.
Company has been under the radar of several Street Analysts.SCYNEXIS Inc is Initiated by Brean Capital to Buy and the brokerage firm has set the Price Target at $16. The Rating was issued on Mar 28, 2016.
SCYNEXIS Inc. is a pharmaceutical company. The Company is engaged in the discovery development and commercialization of anti-infectives. It also provides contract research and development services primarily in the field of animal health. Its lead product candidate SCY-078 is an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. SCY-078 has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species including drug resistant strains. In addition the Company has additional compounds similar to SCY-078. The Company has developed a platform for cyclophilin inhibitors. Its cyclophilin inhibitor platform has two clinical stage compounds: SCY-635 which is a cyclophilin inhibitor for the treatment of dog dry eye and SCY-641 which is a cyclophilin inhibitor with activity similar to cyclosporine for the treatment of viral diseases in humans.